Insider trading on Orchard Therapeutics acquisition by Kyowa Kirin may raise regulatory scrutiny or reputational concerns.
資産への影響 1
Biotech & Genomic Medicine
4151
▼ ネガティブ規制関連度
テーマインパクト
カバレッジ外企業 3
AppliedAI非上場▼ ネガティブ
規制関連度
CEO pleaded guilty to insider trading, damaging company reputation and leadership credibility.
Enstar Group非上場▼ ネガティブ
規制関連度
Insider trading on Sixth Street's acquisition of Enstar may raise regulatory scrutiny or reputational concerns.
Sixth Street Partners非上場± 混在
関連度